bevacizumab Articles
Stock Commentary - Tokyo week to Aug 15
5 September 2005
Stock Commentary - New York
15 August 2005
Japan stock market week to August 1
8 August 2005
Roche to launch Avastin in India
25 July 2005
Roche Rx sales grow three times world rate
25 July 2005
Genentech's Avastin: good AE profile
27 June 2005
Stock Commentary - New York
23 May 2005
Amgen/Abigenix' panitumumab enters Ph III
16 May 2005
Cell Genesys advances GVAX cancer vacc as combo therapy
28 April 2005
Corgentech's cancer drug shows promise in vivo
27 April 2005
Stock Commentary - New York
25 April 2005
Stock Commentary - Europe
25 April 2005
Roche 1st-qtr sales, up 17%, beat estimates
25 April 2005
Japan stock market week to April 4
11 April 2005
Are cancer drug costs leaving benefits behind?
11 April 2005
Stock Commentary - New York
28 March 2005
Stock Commentary - Europe
28 March 2005
Roche's cancer drug Avastin debuts in UK
21 March 2005
PacMab raises fund for new cancer therapy
21 March 2005
OXiGENE's CA4p boosts efficacy of Avastin
21 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Positive trial results for Sanofi-Aventis
7 February 2005
Benefit of Eloxatin chemo plus Avastin
7 February 2005
Positive trial results for Sanofi-Aventis
7 February 2005
Roche disappoints despite 116% net income hike
7 February 2005
New product launches in 2004
31 January 2005
Stock Commentary - New York
24 January 2005
Stock Commentary - Europe
24 January 2005
UPDATE: Roche's Avastin cleared in Europe
24 January 2005
Roche's Avastin cleared by EC
24 January 2005
Stock Commentary - New York
17 January 2005
Editor's views on biotech; clinical trial transparency
17 January 2005
FDA clears Avastin's updated safety label
17 January 2005
Avastin cleared for cancer in Switzerland
10 January 2005
Roche's Genentech gamble pays off
13 December 2004
US CMS cover for off-label cancer drug use
15 November 2004
Roche's Avastin on track in EU
1 November 2004
New cancer drug costs too high for some?
25 October 2004
Innovative drugs and their impact on the future of oncology developments
20 September 2004
Stock Commentary - Europe
23 August 2004
Stock Commentary - New York
23 August 2004
Genentech's Avastin linked to serious blood clots
23 August 2004
Genentech's 2nd-qtr sales rocket 42%
19 July 2004
Roche expands biotech production capacity
28 June 2004
Roche 1st-qtr beats expectations
26 April 2004
Cancer drug developments and attitudes in Japan
26 April 2004
Genentech's sales up 28% for 1st-qtr 2004
19 April 2004
Pegasys still driving Roche's growth
29 March 2004
McClellan at CMS "a boon for biotech"
22 March 2004
Stock Commentary - New York
8 March 2004
Stock Commentary - Europe
8 March 2004
Chugai's 1st 9-mth earnings beat forecasts
8 March 2004
UPDATE: ImClone's Erbitux cleared by FDA
23 February 2004
Tokyo pharma stocks - week to Jan 26
2 February 2004
Tokyo pharma stocks - week to Jan 5
5 January 2004
Roche signs Japanese deal with Chugai
22 December 2003
Roche files Avastin for European approval
15 December 2003
Stock Commentary - Europe
8 December 2003
Genentech and Protein Design resolve patent dispute
8 December 2003
Genentech gains priority review for Avastin BLA
8 December 2003
Tokyo pharma stocks - week to Sept 29
3 November 2003
New wave of drugs offer hope in treatment of colon cancer
3 November 2003
Genentech files BLA with FDA for Avastin
6 October 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
